Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Medicinova Inc
(NQ:
MNOV
)
1.140
+0.010 (+0.88%)
Streaming Delayed Price
Updated: 2:48 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Medicinova Inc
< Previous
1
2
3
4
Next >
MediciNova Receives Gene Therapy Milestone Payment
October 04, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
September 27, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
August 17, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
Medicinova Inc. (NASDAQ: MNOV) Highlighted for Surprising Price Action
March 17, 2023
Via
Investor Brand Network
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
August 16, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
August 15, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
August 14, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates
September 14, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 29, 2023
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today!
Via
InvestorPlace
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
June 29, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
May 14, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
April 30, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
March 09, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 22, 2023
Via
Benzinga
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
February 20, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
February 08, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
January 30, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 25, 2023
Via
Benzinga
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
January 12, 2023
Preliminary results will be presented at the 20th Annual World Congress of the Society for Brain Mapping and Therapeutics
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
January 10, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil
January 09, 2023
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)
January 05, 2023
MN-166 (ibudilast) parenteral formulation showed a favorable safety and tolerability profile in healthy volunteers
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
December 06, 2022
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
December 05, 2022
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 14, 2022
Via
Benzinga
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
July 27, 2022
From
MediciNova, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
September 07, 2022
On Wednesday, 297 companies achieved new lows for the year.
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
July 26, 2022
Via
Benzinga
MediciNova Commences Mid-Stage Non-alcoholic Fatty Liver Disease Study
July 26, 2022
MediciNova (NASDAQ: MNOV) initiated a Phase 2 clinical trial to evaluate MN-001 (tipelukast) for the treatment of patients with non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus...
Via
Benzinga
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
July 26, 2022
From
MediciNova, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.